BIRC5 and neoplasm: Stronger IFN-γ production was identified in PBMCs from patients with histopathological grade III tumors as compared to patients with a grade IV tumor in response to NY-ESO-1 (p = 0.0135); this observation was also found to be true for IFN-γ production to the survivin peptide mix (p = 0.0062, Supplementary Fig. 4).